- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07705594
LuX-Valve Plus System for Severe or Greater Tricuspid Regurgitation
A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of a Transvenous Artificial Tricuspid Valve System in Patients With Severe or Greater Tricuspid Regurgitation
This clinical trial aims to evaluate the safety and effectiveness of the Transvenous Artificial Tricuspid Valve System, LuX-Valve Plus System, Jenscare Scientific Co., Ltd. The study population consists of high-risk patients with severe or greater tricuspid regurgitation (TR) who are ineligible for surgical intervention and have demonstrated inadequate response to optimized medical therapy (OMT).
This is a prospective, multicenter, randomized controlled trial. A total of 111 subjects who meet all inclusion criteria and none of the exclusion criteria will be enrolled. Participants will be randomized in a 2:1 ratio to one of the following groups:
Treatment Group: Transvenous Artificial Tricuspid Valve System implantation + OMT Control Group: OMT alone
All subjects will undergo serial follow-up assessments pre-treatment, during the treatment period, and post-procedure at 30 days, 3 months, 6 months, 1 year, and annually through 2-5 years. A summary report will be submitted to the regulatory authority at the 6-month time point.
Subjects in the treatment group will have one extra follow-up visit at 7 days ± 3 days post-procedure or prior to discharge (whichever occurs first).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Zhongshan hospital, Fudan university
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age ≥ 65 years
- Severe or greater TR (TR ≥ 3+ / 4+ by echocardiography)
- High surgical risk or inoperable per heart team (TRI-SCORE ≥6, STS ≥8%, EuroSCORE II ≥3%, etc.) AND symptomatic despite GDMT (≥1 month diuretics, stable regimen for ≥2 weeks)
- Suitable for TTVR per heart team
- NYHA III-IV
- Signed ICF and willing to comply with follow-up
Exclusion Criteria:
- Anatomy unsuitable for device procedure
- LVEF < 50%
- SPAP > 60 mmHg by TTE (unless RHC confirms ≤60 mmHg)
- Aortic/mitral/pulmonary valve disease requiring surgery
- Prosthetic valve replacement within 6 months or moderate/severe dysfunction
- Ebstein anomaly or RV dysplasia
- RVOT obstruction or intracardiac mass
- Active endocarditis within 90 days, or antibiotics for infection within 14 days
- CV/cardiac/cervical surgery within 30 days
- Stroke within 90 days
- Unable to tolerate anticoagulation/antiplatelet therapy
- eGFR < 30 mL/min/1.73m² or on RRT
- MELD-Albumin ≥ 12
- Severe respiratory dysfunction (unsuitable for general anesthesia)
- Active GI bleeding/ulcer within 90 days
- Cardiogenic shock or hemodynamic instability within 30 days
- Untreated severe CAD or ACS within 30 days
- Life expectancy ≤ 1 year
- Known allergy to device components or study drugs
- Pregnancy or lactation (or planned pregnancy)
- Enrolled in another interventional trial (not reached primary endpoint)
- Other conditions deemed unsuitable per investigator
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment Group
LuX-Valve Plus System+OMT
|
Transvenous tricuspid valve replacement with Lux-Valve Plus System in patients with severe or greater Tricuspid Regurgitation despite optimal medical therapy (OMT)
|
|
Ander: Control Group
OMT only
|
Optimal medical therapy (OMT) as the control group for patients with severe or greater tricuspid regurgitation
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence rate of composite endpoint events
Tijdsspanne: 6 months post-treatment
|
Percentage (%) of participants achieving composite clinical success at 6 months. Composite clinical success is defined as meeting all of the following criteria:
|
6 months post-treatment
|
|
Rate of Major Adverse Events (MAE)
Tijdsspanne: 30 Day Post-treatment
|
The major adverse event (MAE) rate is defined as the occurrence of any of the following: Cardiac death Myocardial infarction Stroke New-onset renal failure requiring renal replacement therapy after the procedure Major bleeding (Grade ≥3b according to TVARC) Tricuspid valve re-intervention Device puncture site and vascular access complications Major cardiac structural complications Device-related pulmonary embolism Arrhythmia or conduction block requiring permanent pacemaker implantation |
30 Day Post-treatment
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CP-TVS02-C2401
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .